Skip to main content
Home > Week in Review > Management

Chronological Index of : Management Tracks

 Current Issue
  • Ablynx board of directors update

    Ablynx N.V. (Euronext:ABLX), Ghent, Belgium Business: Antibodies Appointed: Russell Greig, formerly president of international pharmaceuticals and SVP of worldwide business development at GlaxoSmithKline plc; and Roger …

    Published on 3/4/2013
  • Bausch + Lomb management update

    Bausch + Lomb Inc., Rochester, N.Y. Business: Pharmaceuticals Hired: Robert Bertolini as president and CFO, formerly EVP and CFO of Schering-Plough Corp., which merged with Merck & Co. Inc.; he replaces Brian Harris

    Published on 3/4/2013
  • Cannabis Science management update

    Cannabis Science Inc. (OTCBB:CBIS), Colorado Springs, Colo. Business: Cancer, Autoimmune, Infectious Hired: Richard Ogden as CSO, formerly director of HIV scientific affairs at Pfizer Inc.

    Published on 3/4/2013
  • Cellectis management update

    Cellectis S.A. (Euronext:ALCLS), Paris, France Business: Gene/Cell therapy, Genomics Hired: Pierre Schwich as CFO; he replaces Marc Le Bozec, who is departing

    Published on 3/4/2013
  • Cytori management update

    Cytori Therapeutics Inc. (NASDAQ:CYTX; Xetra:XMPA), San Diego, Calif. Business: Gene/Cell therapy, Musculoskeletal Hired: Steven Kesten as EVP and CMO, formerly VP and CMO of Uptake Medical Corp.

    Published on 3/4/2013
  • Definiens management update

    Definiens AG, Munich, Germany Business: Bioinformatics Hired: Ralf Huss as CMO, formerly global head of histopathology and tissue biomarker at Roche's Roche Diagnostics unit

    Published on 3/4/2013
  • Dezima board of directors update

    Dezima Pharma B.V., Naarden, the Netherlands Business: Cardiovascular Appointed: Marco Boorsma, principal at Forbion Capital Partners; Wil Hazenberg, partner at BioGeneration Ventures; and Somu Subramaniam, managing …

    Published on 3/4/2013
  • Elan management update

    Elan Corp. plc (NYSE:ELN), Dublin, Ireland Business: Drug delivery, Neurology, Autoimmune Hired: John Given as general counsel, formerly senior corporate partner at A&L Goodbody

    Published on 3/4/2013
  • Endo management update

    Endo Health Solutions Inc. (NASDAQ:ENDP), Chadds Ford, Pa. Business: Neurology Hired: Rajib De Silva as president, CEO and a director, effective March 18, formerly president of Valeant Pharmaceuticals International Inc…

    Published on 3/4/2013
  • Intersect board of directors update

    Intersect ENT Inc., Palo Alto, Calif. Business: Infectious Appointed: Casper de Clercq, partner at Norwest Venture Partners

    Published on 3/4/2013
  • Ipsen management update

    Ipsen Group (Euronext:IPN; Pink:IPSEY), Boulogne-Billancourt, France Business: Cancer, Endocrine/Metabolic, Neurology Hired: Christel Bories as deputy CEO, effective March 11

    Published on 3/4/2013
  • Kala Pharmaceuticals management update

    Kala Pharmaceuticals Inc., Waltham, Mass. Business: Ophthalmic, Drug delivery Hired: Kim Brazzell as CMO, formerly EVP of medical and scientific affairs at Inspire Pharmaceuticals Inc., which Merck & Co. Inc. acquired

    Published on 3/4/2013
  • Takeda management update

    Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Business: Pharmaceuticals Transitioned: Iwaaki Taniguchi to SVP of the corporate finance and controlling department from associate director of the department

    Published on 3/4/2013
  • Alchemia management update

    Alchemia Ltd. (ASX:ACL), Brisbane, Australia Business: Chemistry, Cancer, Hematology Transitioned: Charles Walker to CEO from CFO; he succeeds CEO and Managing Director Peter Smith

    Published on 2/25/2013
  • Alexion management update

    Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), Cheshire, Conn. Business: Hematology, Autoimmune, Cancer Departing: Tom Dubin as chief legal officer Hired: John Moriarty as SVP and general counsel; and Frank Wright as SVP …

    Published on 2/25/2013
  • Amyris management update

    Amyris Inc. (NASDAQ:AMRS), Emeryville, Calif. Business: Biomanufacturing Hired: Zanna McFerson as CBO, effective March 4, formerly VP at Cargill Inc.

    Published on 2/25/2013
  • AntriaBio management update

    AntriaBio Inc. (OTCQB:ANTB), Menlo Park, Calif. Business: Endocrine/Metabolic Hired: Nevam Elam as president and CEO, formerly CEO of AeroSurgical Ltd.; and Sankaram Mantripragada as CSO, formerly VP of R&D at PR …

    Published on 2/25/2013
  • Bach Pharma management update

    Bach Pharma Inc., North Andover, Mass. Business: Neurology Transitioned: Daniel Cato, a director, to president from VP of international regulatory affairs

    Published on 2/25/2013
  • Chimerix board of directors update

    Chimerix Inc., Durham, N.C. Business: Infectious Appointed: Ernest Mario, chairman and CEO of Capnia Inc., as chairman

    Published on 2/25/2013
  • CombiMatrix management update

    CombiMatrix Corp. (NASDAQ:CBMX), Mukilteo, Wash. Business: Bioinformatics, Microarrays, Diagnostic Retiring: Judd Jessup as CEO, effective March 15; he will be succeeded by Chief Commercial Officer Mark McDonough

    Published on 2/25/2013
  • Curis management update

    Curis Inc. (NASDAQ:CRIS), Lexington, Mass. Business: Cancer Hired: Ali Fattaey as president and COO, formerly president and CEO of ACT Biotech Inc.

    Published on 2/25/2013
  • EnteroMedics management update

    EnteroMedics Inc. (NASDAQ:ETRM), St. Paul, Minn. Business: Endocrine/Metabolic, Gastrointestinal Transitioned: Greg Lea to COO while remaining SVP and CFO

    Published on 2/25/2013
  • InterMune management update

    InterMune Inc. (NASDAQ:ITMN), Brisbane, Calif. Business: Pulmonary, Musculoskeletal Hired: Sean Nolan as EVP and CBO, a newly created position, formerly VP and chief commercial officer of Reata Pharmaceuticals Inc.

    Published on 2/25/2013
  • Lundbeck board of directors update

    H. Lundbeck A/S (CSE:LUN), Copenhagen, Denmark Business: Neurology Departing: Mats Pettersson as chairman

    Published on 2/25/2013
  • MethylGene management update

    MethylGene Inc. (TSX:MYG), Montreal, Quebec Business: Cancer, Infectious Hired: Mark Gergen as EVP and COO, formerly SVP of corporate development at Amylin Pharmaceuticals Inc., which Bristol-Myers Squibb Co. acquired

    Published on 2/25/2013

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993